Nasal Spray Peptides: What Reaches the Body and What the Labels Say

Only a small share of a peptide sprayed into the nose reaches the bloodstream, and the approved nasal sprays prove it with numbers. The label for calcitonin salmon nasal spray puts its bioavailability at 3% to 5% of an intramuscular injection. That is why the few peptides that are approved as nasal sprays are potent molecules given in carefully tested devices, and why a research peptide in a spray bottle tells you very little about how much of it is absorbed.

This guide covers what the approved sprays' labels say, what intranasal research has measured, and what is missing for research sprays.

Peptides approved as nasal sprays

Three peptide medicines with current US labels show how the route works in practice:

A few patterns run through all three labels:

• Absorption is low and variable. Calcitonin's label gives the figure directly. Desmopressin's label warns that the state of the nasal lining changes how much gets in.

• The nose itself reacts. Calcitonin's label lists rhinitis (12%), nosebleeds (4%) and sinusitis (2%) as the most common nasal reactions in postmenopausal patients.

• Technique is part of the dose. Synarel's instructions treat sneezing and decongestants as things that change absorption, and the calcitonin and desmopressin labels require the pump to be primed before first use.

• Storage differs by product. Calcitonin's unopened bottle is refrigerated, then kept at room temperature once in use for up to 30 days (2 mL bottle) or 35 days (3.7 mL bottle). Synarel and desmopressin are stored at room temperature, and Synarel's label adds protection from light.

What intranasal research has measured

Beyond the approved sprays, several peptides have been given intranasally in studies. The results show both what the route can do and how much depends on the molecule:

• GRF(1-29), the sermorelin peptide. In healthy men, nasal absorption was low, with a bioavailability of only 3–5%. The largest growth hormone response came at about 50 µg/kg intranasally, roughly matching 1 µg/kg given intravenously (Wilton 1993). See the sermorelin profile.

• Kisspeptin-54. A randomised, placebo-controlled study found that intranasal kisspeptin-54 raised luteinising hormone in healthy men and women and in women with hypothalamic amenorrhoea, without reported side effects. The spray formulation was stable for up to 60 days at 4 °C (Mills 2025).

• Oxytocin. In a 24-week phase 2 trial in 290 children and adolescents with autism, intranasal oxytocin made no significant difference to social or cognitive measures compared with placebo (Sikich 2021). A spray that is absorbed is not the same as a spray that works.

The ratio in the GRF(1-29) study is the clearest illustration of the route: about fifty times the intravenous amount was needed to produce a similar response.

Research peptides sold as sprays

Semax and selank were developed in Russia and are used intranasally there; their human literature is a small set of Russian-language studies, and neither is approved in the United States. Other research peptides are also sold in spray bottles.

What a research spray lacks is everything the approved labels above are built on:

• No measured absorption. Nobody has published how much of that product, in that bottle, reaches the bloodstream.

• No tested formulation. Approved sprays list their inactive ingredients and were tested in their own pump. A research spray's solution and device are whatever the seller chose.

• No storage data. The labels above give tested storage conditions and in-use periods. A research spray has none, so there is no published figure for how long it stays intact once opened.

• Unclear route. Some listings do not even say whether a spray is meant for the nose or the mouth. Peptide Library's shop keeps nasal sprays separate from sprays whose route the seller does not state, and never assumes one.

The semax vs selank comparison covers what is known about those two specifically, and the oral peptides guide covers the other non-injected route.

Frequently asked questions

Do nasal spray peptides work?

Some do, as approved medicines with tested absorption: calcitonin, nafarelin and desmopressin all have nasal spray labels. Absorption is low, around 3–5% for calcitonin, so the molecule and the device matter. For research sprays, absorption has not been measured.

Which peptides are FDA-approved as nasal sprays?

Among peptides with current US labels: calcitonin salmon, nafarelin (Synarel) and desmopressin. Each is approved for a specific condition.

How much of a nasal spray is absorbed?

It depends on the molecule and the product. Calcitonin's label gives 3–5% relative to intramuscular injection; a study of GRF(1-29) measured 3–5% as well. Other peptides have no published figure.

Why are most peptides injected instead?

Because injection delivers a known amount. The labels and studies above show that the nose absorbs only a small, variable share of a peptide dose.